INCB054329

CAS No. 1628607-64-6

INCB054329( INCB 054329 )

Catalog No. M12432 CAS No. 1628607-64-6

INCB054329 is a novel potent, orally bioactive BET inhibitor that inhibits binding of BRD2, BRD3 and BRD4 to an acetylated histone H4 peptide with low nanomolar potency.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 140 Get Quote
10MG 222 Get Quote
25MG 447 Get Quote
50MG 651 Get Quote
100MG 888 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    INCB054329
  • Note
    Research use only, not for human use.
  • Brief Description
    INCB054329 is a novel potent, orally bioactive BET inhibitor that inhibits binding of BRD2, BRD3 and BRD4 to an acetylated histone H4 peptide with low nanomolar potency.
  • Description
    INCB054329 is a novel potent, orally bioactive BET inhibitor that inhibits binding of BRD2, BRD3 and BRD4 to an acetylated histone H4 peptide with low nanomolar potency; inhibits expression of c-MYC and induced HEXIM1 in myeloma cell lines; inhibits growth of the majority of myeloma, AML, and lymphoma cell lines with IC50<100 nM; induces G1 arrest and cell apoptosis consistent with increased expression of pro-apoptotic regulators; inhibits tumor growth in vivo.
  • In Vitro
    INCB054329 is a bromodomain and extra-terminal motif (BET) inhibitor. INCB054329 inhibits binding of BRD2, BRD3 and BRD4 to an acetylated histone H4 peptide with low nanomolar potency. In myeloma cell lines, treatment with INCB054329 inhibits expression of c-MYC and induced HEXIM1. The majority of myeloma, AML, and lymphoma cell lines tested are growth inhibited by INCB054329 with potencies less than 200 nM. Selectivity is seen when compared with nontransformed cells as the potency for growth inhibition of IL-2 stimulated T-cells from normal donors is greater than 1300 nM. Cell cycle analysis reveals treatment-induced G1 arrest. Furthermore in both AML and lymphoma cell lines, INCB054329 induces apoptosis consistent with increased expression of pro-apoptotic regulators.
  • In Vivo
    Oral administration of INCB054329 inhibits tumor growth in several models of hematologic cancers. In the MM1.S multiple myeloma xenograft model, inhibition of tumor growth is correlated with reduction of c-MYC levels. PK-PD analysis shows c-MYC suppression is associated with an IC50 value of less than 100 nM in vivo.
  • Synonyms
    INCB 054329
  • Pathway
    Chromatin/Epigenetic
  • Target
    Bromodomain
  • Recptor
    Bromodomain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1628607-64-6
  • Formula Weight
    348.362
  • Molecular Formula
    C19H16N4O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 100 mg/mL 287.06 mM
  • SMILES
    O=C1N2[C@H](COC3=C2C(N1)=CC=C3C4=C(ON=C4C)C)C5=CC=CC=N5
  • Chemical Name
    (S)-6-(3,5-dimethylisoxazol-4-yl)-3-(pyridin-2-yl)-3,4-dihydro-5-oxa-1,2a-diazaacenaphthylen-2(1H)-one

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Phillip CC Liu, et al. DOI: 10.1158/1538-7445.AM2015-3523 Published August 2015 2. Pérez-Salvia M, et al. Epigenetics. 2017 May 4;12(5):323-339.
molnova catalog
related products
  • AZD-5153

    AZD-5153 is a potent, selective, bivalent and orally available BET/BRD4 bromodomain with IC50 of 5 nM.

  • GNE-207

    GNE-207 (GNE207) is a novel potent, selective, orally active CBP/p300 bromodomain with IC50 of 1.0 nM.

  • CN750

    CN750 (CN-750) is novel BRD4 (BD1, 2) inhibitor with IC50 of 44 nM, MV4-11 IC50 of 0.54 uM.